A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
About the study
The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279.
All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules.
Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- A diagnosis of GPP or EP prior to the screening visit.
- Candidate for phototherapy or systemic therapy.
EXCLUSION CRITERIA
Exclusion Criteria:
- Other forms of psoriasis.
- History of recent infection.
- Any prior exposure to TAK-279, or participation in any study that included a TYK2 inhibitor.
Other protocol defined inclusion/exclusion criteria apply.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Generalized Pustular Psoriasis,Erythrodermic Psoriasis
Age
18+
Phase
PHASE3
Participants Needed
20
Est. Completion Date
Mar 27, 2026
Treatment Type
INTERVENTIONAL
Sponsor
Takeda
ClinicalTrials.gov NCT Identifier
NCT06323356
Study Number
TAK-279-PsO-3005
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?